Diamyd partners its diabetes vaccine with J&J unit

Wednesday 23 June 2010

Diamyd Medical AB has partnered its lead antigen-based therapy for the treatment and prevention of Type1 diabetes with Ortho-McNeil-Janssen Pharmaceuticals Inc (OMJPI), a unit of Johnson & Johnson.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Sweden